Clinical trials: Japan’s opt-out policy raises risks of adverse drug responses

Mira Namba,Yudai Kaneda,Akihiko Ozaki,Tetsuya Tanimoto

DOI: https://doi.org/10.1038/d41586-024-00301-7

IF: 64.8

2024-02-06

Nature

Abstract:Letter to the Editor

multidisciplinary sciences

What problem does this paper attempt to address?

High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: a questionnaire survey

Chieko Kurihara,Hideo Kusuoka,Shunsuke Ono,Naoko Kakee,Kazuyuki Saito,Kenji Takehara,Kiyokazu Tsujide,Yuzo Nabeoka,Takuya Sakuhiro,Hiroshi Aoki,Noriko Morishita,Chieko Suzuki,Shigeo Kachi,Emiko Kondo,Yukiko Komori,Tetsu Isobe,Shigeru Kageyama,Hiroshi Watanabe

DOI: https://doi.org/10.1371/journal.pone.0084998

IF: 3.7

2014-01-08

PLoS ONE

Abstract:Introduction: International norms and ethical standards have suggested that compensation for research-related injury should be provided to injured research volunteers. However, statistical data of incidence of compensation claims and the rate of awarding them have been rarely reported. Method: Questionnaire surveys were sent to pharmaceutical companies and medical institutions, focusing on industry-initiated clinical trials aiming at new drug applications (NDAs) on patient volunteers in Japan. Results: With the answers from pharmaceutical companies, the incidence of compensation was 0.8%, including 0.06% of monetary compensation. Of the cases of compensation claims, 99% were awarded. In turn, with the answers from medical institutions, the incidence of compensation was 0.6%, including 0.4% of serious but not death cases, and 0.04% of death cases. Furthermore, most claims for compensation were initiated by medical institutions, rather than by the patients. On the other hand, with the answers from clinical trial volunteers, 3% of respondents received compensations. These compensated cases were 25% of the injuries which cannot be ruled out from the scope of compensation. Conclusion: Our study results demonstrated that Japanese pharmaceutical companies have provided a high rate of compensation for clinical trial-related injuries despite the possibility of overestimation. In the era of global clinical development, our study indicates the importance of further surveys to find each country's compensation policy by determining how it is being implemented based on a survey of the actual status of compensation coming from statistical data.
Safety Evaluation and Information Provision for Appropriate Drug Usage in Elderly Patients in Japan

Makoto Onohara,Mamoru Narukawa

DOI: https://doi.org/10.1248/bpb.b24-00437

Abstract:The elderly Japanese population is growing rapidly due to increasing longevity and declining birth rates. These findings have implications for drug development and safety in elderly patients; however, the Japanese stakeholders have been slow to adapt. This study aimed at examining methods for providing sufficient information on safe use of pharmaceuticals in elderly patients in Japan. For new drugs recently approved in Japan for diseases with a high prevalence among the elderly, we investigated the state of safety information provision for elderly patients through the package insert and also safety data evaluation in elderly patients in clinical studies. Of the 64 targeted drugs, only 14 provided geriatric use information based on clinical study data or indication, 38 had general cautionary descriptions, and 12 did not have geriatric use information. Most drugs met the recommendation of enrolling >100 elderly patients in the clinical development program. However, a discrepancy was observed in the proportion of elderly patients in clinical trials compared to that in real-world clinical setting. Twenty-nine drugs compared the incidence of key adverse events (AEs) in elderly and younger patients, whereas 25 only reported the overall incidence of AEs. To improve healthcare outcomes, healthcare professionals need access to sufficient safety information through package inserts containing data from clinical trials. Marketing authorization holders and regulatory authorities must work together to ensure that such safety information based on sufficient data is included in package inserts.
Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan

T Ueno,Y Asahina,A Tanaka,H Yamada,M Nakamura,Y Uyama

DOI: https://doi.org/10.1038/clpt.2013.223

2013-11-08

Abstract:Although the number of global clinical trials (GCTs) conducted in multiple countries including Japan has increased recently, it is not clear how much these GCTs help in reducing the lag in drug development (LDD: difference between the submission dates for new drug applications (NDAs) in the United States and Japan). We examined the effects of various clinical development strategies on LDD because the development period depends on what types of clinical trials were conducted for the Japanese NDA. Although various drug development strategies are available, deciding early on an appropriate strategy is a key to minimizing the LDD in Japan. The inclusion of GCTs in the clinical development strategy is also important; simultaneously, the smaller sample size of the Japanese population should be taken into consideration. Furthermore, reinforcement of Japan's capability to lead drug development may also be important in providing innovative drugs to Japanese patients without any significant LDD.

pharmacology & pharmacy
Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study

Sadao Jinno,Akira Onishi,Shuhei Hattori,Maureen Dubreuil,Yo Ueda,Keisuke Nishimura,Takaichi Okano,Hirotaka Yamada,Wataru Yamamoto,Koichi Murata,Hideo Onizawa,Kosuke Ebina,Yuichi Maeda,Yonsu Son,Hideki Amuro,Ryota Hara,Kenichiro Hata,Hideyuki Shiba,Masaki Katayama,Ryu Watanabe,Motomu Hashimoto,Jun Saegusa

DOI: https://doi.org/10.1093/rheumatology/keae081

2024-02-06

Rheumatology

Abstract:Abstract Objectives This multicentre, retrospective study aimed to compare retention and reasons for discontinuation between Janus kinase inhibitors (JAKi) and biologic DMARDs in patients with elderly-onset rheumatoid arthritis (EORA). Methods Patients with RA enrolled in a Japanese multicentre observational registry between 2015 and 2022 were included. EORA was defined as RA with onset at age 60 or over. To adjust confounding factors by indication for initiation of TNF inhibitors (TNFi), IL-6 inhibitors (IL-6i), cytotoxic T-lymphocyte associated antigen 4 immunoglobulin (CTLA4-Ig) blockers, or JAKi, a propensity score based on baseline characteristics was used to compare drug retention. To assess the reasons for discontinuation, retention rates for ineffectiveness, adverse events and remission were analysed as secondary outcomes. Results A total of 572 patients with 835 treatment courses were identified (314 TNFi, 175 IL-6i, 228 CTLA4-Ig and 118 JAKi). After adjusting for differences in baseline characteristics, drug retention was significantly higher for IL-6i (hazard ratio [HR] = 0.38; 95% CI: 0.27, 0.55; P < 0.01) as compared with TNFi. Discontinuation due to lack of effectiveness was lower with JAKi (HR = 0.38; 95% CI: 0.22, 0.66; P < 0.01) and IL-6i (HR = 0.29; 95% CI: 0.19, 0.46; P < 0.01) as compared with TNFi although CTLA4-Ig had a similar HR to TNFi. The adjusted incidence of discontinuation due to adverse events was higher for JAKi (HR = 2.86; 95% CI: 1.46, 5.59; P < 0.01) than for TNFi. Conclusion In EORA patients, IL-6i and JAKi had longer retention and less discontinuation due to ineffectiveness than TNFi. The potential risks of JAKi should be approached with an individualized perspective.

rheumatology
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals

Hayase Hakariya,Frank Moriarty,Akihiko Ozaki,Shai Mulinari,Hiroaki Saito,Tetsuya Tanimoto

DOI: https://doi.org/10.1111/cts.13879

Abstract:Regulatory authorities must balance ensuring evidence of efficacy and safety of new drugs. Various regulatory pathways, such as the accelerated approval program in the United States (US), allow authorities to quickly approve drugs for severely ill patients by granting market authorization based on surrogate end points and pending confirmatory trials. In this cross-sectional study, we considered 23 indications of cancer drugs that received accelerated approval by the US Food and Drug Administration (FDA) but were subsequently withdrawn as of April 2023. Our investigation extended to assessing the regulatory status of these accelerated approvals in the European Union (EU) and Japan, examining relevant regulatory documents and identifying factors contributing to the withdrawal in the United States. Comparing regions, we found that for 52% (12/23) and 30% (7/23) of withdrawn accelerated approvals in the United States, sponsors had also sought marketing authorization from the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), respectively. As of the April 30, 2023 study cutoff date, 83% (10/12) of drug-indication pairs remained approved by the EMA, while the PMDA retained 100% (7/7). For these indications, the time from FDA withdrawal until the study cutoff date ranged from 0.23 years to 11.45 years for EMA approvals (median: 1.28 years) and 1.10 years to 11.45 years for PMDA approvals (median: 3.22 years). These findings highlight substantial regulatory discrepancies concerning cancer drugs with unconfirmed benefits. Addressing these discrepancies may involve requiring pharmaceutical companies to confirm clinical benefits using more robust end points and fostering international harmonization in regulators' assessment.
Exacerbation rates in Japanese patients with obstructive lung disease: A subanalysis of the prospective, observational NOVELTY study

Tomotaka Kawayama,Kenichi Takahashi,Toshikazu Ikeda,Kenya Fukui,Naoyuki Makita,Naoki Tashiro,Junpei Saito,Toshihiro Shirai,Hiromasa Inoue

DOI: https://doi.org/10.1016/j.alit.2023.08.003

Abstract:Background: Although clinical trials including asthma and COPD patients have revealed much about exacerbation frequencies, most studies are limited in that they recruited patients only with a clear diagnosis of one disease or the other, based on conventional diagnostic criteria, which may exclude many real-world patients with mixed symptoms. Methods: NOVELTY is a global prospective observational study of patients with asthma and/or COPD from real-world practice. In this subanalysis, we compared patient characteristics of obstructive pulmonary diseases between the Japanese population (n = 820) and the overall population excluding Japanese patients (n = 10,406). Results: The Japanese population had fewer exacerbations than the overall population across most of the physician-assessed disease severities and all diagnoses. The difference in exacerbation frequencies was more prominent in patients with COPD and asthma + COPD. The Japanese population was older, had higher former smoking rates, lower BMI, fewer respiratory symptoms, and better health-related quality of life compared with the overall population across all diagnoses. Conclusions: We clarified differences in patient characteristics among patients with asthma and/or COPD in Japan compared with non-Japanese patients. Importantly, we found that Japanese patients with asthma and/or COPD had significantly fewer exacerbations compared with patients overall. The results from our study may contribute to the development of precision medicine and guidelines specific to Japan.
Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan

Mitsuru Ishibai,Megumi Kai,Hirokazu Wakuda,Ichiro Oikawa,Naoto Uemura

DOI: https://doi.org/10.1208/s12248-024-00980-0

2024-10-11

The AAPS Journal

Abstract:Anti-drug antibodies (ADAs) generated in response to biopharmaceuticals can significantly impact pharmacokinetics (PK) and overall drug efficacy. Thus, the ICH M4 guidelines mandate summarizing immunogenicity data from clinical trials in drug approval applications. However, following the approval of the first antibody drug in Japan in 2001, no cross-sectional investigation has focused on immunogenicity during the regulatory review process. Therefore, this study aims to examine the review reports and prescribing information of antibody drugs approved in Japan to identify key points related to immunogenicity evaluation. We conducted a cross-sectional analysis of review reports for antibody drugs approved between June 2001 and July 2022 by the Japanese regulatory authority. Specifically, we evaluated the ADA positivity rate, presence of neutralizing antibodies, antibody titers, and effects of ADA on PK, efficacy, and safety. We also compared this information with that provided in the prescribing information. Our analysis revealed that the ADA positivity rate and its effects on PK, efficacy, and safety were critical aspects of the review process. The emphasis on these factors varied depending on the number of applications and disease area. The information presented in the prescribing information was largely consistent with that discussed in the review reports. Overall, this study provides the first cross-sectional evaluation of immunogenicity considerations in the regulatory review of antibody drugs in Japan. Our findings can contribute to the efficiency of clinical trial planning and preparation of approval applications, to potentially improve the overall drug development process and address the drug loss problem in Japan.

pharmacology & pharmacy
Implementation of Japan's First Clinical Research Regulatory Law: Background, Overview, and Challenges

Akira Akabayashi,Eisuke Nakazawa,Aru Akabayashi

DOI: https://doi.org/10.1007/s10730-019-09379-3

HEC Forum

Abstract:In April 2018, Japan's first law regulating clinical research went into effect. The law aimed to strengthen regulations on research integrity and conflicts of interest, which had been limited under existing administrative guidelines; the law also provided stipulations for legal penalties. The scope of the new regulations, however, is limited entirely to studies that evaluate unapproved drugs or the off-label use of approved drugs, and those that receive funding from companies. On the other hand, the law's application brings numerous complications, including the establishment of new review committees, troublesome procedures for transitioning studies that are currently underway, and ambiguities about the scope of what constitutes best efforts. Thus, the change has led to substantial strain and confusion in the field. This paper offers an overview of the law and its background, and discusses its future prospects from the practical standpoint of managing ethics committees and providing research ethics support in the field.
Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

Kojiro Maeda,Masayuki Kaneko,Mamoru Narukawa,Teruyo Arato

DOI: https://doi.org/10.1186/s13023-017-0690-5

2017-08-23

Orphanet Journal of Rare Diseases

Abstract:BackgroundThe unmet medical needs of individuals with very rare diseases are high. The clinical trial designs and evaluation methods used for ‘regular’ drugs are not applicable in the clinical development of ultra-orphan drugs (<1000 patients) in many cases. In order to improve the clinical development of ultra-orphan drugs, we examined several points regarding the efficient evaluations of drug efficacy and safety that could be conducted even with very small sample sizes, based on the review reports of orphan drugs approved in Japan.ResultsThe clinical data packages of 43 ultra-orphan drugs approved in Japan from January 2001 to December 2014 were investigated. Japanese clinical trial data were not included in the clinical data package for eight ultra-orphan drugs, and non-Japanese clinical trial data were included for six of these eight drug. Japanese supportive data that included retrospective studies, published literature, clinical research and Japanese survey results were clinical data package attachments in 22 of the 43 ultra-orphan drugs. Multinational trials were conducted for three ultra-orphan drugs. More than two randomized controlled trials (RCTs) were conducted for only 11 of the 43 ultra-orphan drugs. The smaller the number of patients, the greater the proportion of forced titration and optional titration trials were conducted. Extension trials were carried out for enzyme preparations and monoclonal antibodies with high ratio. Post-marketing surveillance of all patients was required in 36 of the 43 ultra-orphan drugs.For ultra-orphan drugs, clinical endpoints were used as the primary efficacy endpoint of the pivotal trial only for two drugs. The control groups in RCTs were classified as follows: placebo groups different dosage groups, and active controls groups. Sample sizes have been determined on the basis of feasibility for some ultra-orphan drugs.We provide “Draft Guidance on the Clinical Development of Ultra-Orphan Drugs” based on this research.ConclusionsThe development of ultra-orphan drugs requires various arrangements regarding evidence collection, data sources and the clinical trial design. We expect that this draft guidance is useful for ultra-orphan drugs developments in future.

genetics & heredity,medicine, research & experimental
Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan

Anju Murayama,Naoki Shin,Kenichi Higuchi,Isha Kohli,Hinari Kugo,Yuki Senoo

DOI: https://doi.org/10.1080/23744235.2024.2309351

2024-02-03

Infectious Diseases

Abstract:The authors appreciate Ms. Megumi Aizawa for her dedicated support of our research project. As this study was a retrospective analysis of publicly available data and met the definition of non-human subjects' research, no institutional board review and approval were required. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline. Not applicable. Not applicable. Anju Murayama : conceptualisation; methodology; resource; software; formal analysis; investigation; writing – original draft; writing – review and editing; visualisation; study administration; supervision. Naoki Shin : conceptualisation; resource; formal analysis; investigation; writing – original draft; writing – review and editing. Kenichi Higuchi : conceptualisation; resource; software; investigation; writing – original draft; writing – review and editing. Isha Kohli : conceptualisation; writing – original draft; writing – review and editing Hinari Kugo : conceptualisation; resource; investigation; writing – review and editing Yuki Senoo : conceptualisation; methodology; resource; formal analysis; investigation; writing – original draft; writing – review and editing Not applicable. The authors declare that there were no conflicts of interest for this study. During the preparation of this work, the authors used ChatGPT version 4.0 to check and correct grammatical and spelling errors. After using this tool, the authors carefully reviewed and edited the content as needed and take full responsibility for the content of the publication. All data used in this study is available from Yen For Docs database run by Medical Governance Research Institute (https://yenfordocs.jp/) and each pharmaceutical companies belonging to the Japan Pharmaceutical Manufacturers Association. Due to the privacy restriction, the datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

infectious diseases
Guidelines for clinical evaluation of anti‐cancer drugs

Hironobu Minami,Naomi Kiyota,Shiro Kimbara,Yuichi Ando,Tomoya Shimokata,Atsushi Ohtsu,Nozomu Fuse,Yasutoshi Kuboki,Toshio Shimizu,Noboru Yamamoto,Kazuto Nishio,Yutaka Kawakami,Shin‐ichi Nihira,Kazuhiro Sase,Takahiro Nonaka,Hideaki Takahashi,Yukiko Komori,Koshin Kiyohara

DOI: https://doi.org/10.1111/cas.14967

IF: 5.7

2021-06-08

Cancer Science

Abstract:<p>Clinical studies intended for regulatory approval must demonstrate the clinical benefits of the drug in a target population. Clinical development of a drug proceeds via stepwise clinical studies; after safety and pharmacokinetics are evaluated and the recommended dosage and administration are determined, efficacy and safety are evaluated in an exploratory manner, and finally clinical benefits are compared with conventional standard therapies. Guidelines for the clinical evaluation of anti‐cancer drugs in Japan were established in 1991 and amended in 2006 after molecular‐targeted drugs were introduced. Recent progress in development of drugs acting on the immune system and cancer genomic medicine targeting rare but important molecular subtypes have altered the strategy for development of anti‐cancer drugs. It is often difficult to conduct a confirmatory randomized controlled study using overall survival as the primary endpoint in rare molecular subtypes, and the primary evaluation of the efficacy of some drugs and subsequent approval is based on the tumor response. Since conducting clinical studies for rare subtypes solely within Japan is difficult, drug development needs to be conducted within a global study. However, this required robust monitoring to detect possible ethnic differences in pharmacokinetics and drug efficacy. Development using the conditional approval system for drugs enforced in 2020 may be considered, where clinical utility is evaluated based on surrogate endpoints. Because of these changes, we have revised the guidelines for the clinical evaluation of anti‐cancer drugs in Japan. To promote global development of anticancer drugs involving Japan, the guidelines have been translated into English.</p>

oncology
Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency

Ken Hatogai,Yuka Kato,Chikara Hirase

DOI: https://doi.org/10.1080/0284186X.2021.1871946

IF: 4.311

2021-01-19

Acta Oncologica

Abstract:Comparative studies often cannot be conducted for cancer types with a small patient population. We reviewed the efficacy evaluations of new drug approvals in Japan based on the results of single-arm clinical trials. We reviewed review reports on anticancer agents approved in Japan between 2006 and 2019 that are publicly available on the website of the Pharmaceuticals and Medical Devices Agency, Japan. The number of single-arm trial-based approvals increased, with a total of 43 drugs approved during the study period. Compared with comparative trial-based approvals, single-arm trial-based approvals had a tendency toward more biomarker-related indications (37.2% vs 22.6%, p = .053), as well as more approvals for hematological malignancies, orphan designation, and response-related outcomes as the primary endpoint. Only 13 of the pivotal trials of single-arm trial-based approvals had a predefined threshold for efficacy based on the same target population as the pivotal trial, and nearly half of the trials did not have an appropriate predefined threshold for efficacy. In particular, the efficacy thresholds for clinical trials for 4 molecular targeted agents were set based on the results of the nonbiomarker-selected population. Evidence on standard cancer therapies for rare molecular subtypes is lacking. External control data from registries might support the efficacy evaluations of new drugs for newly established rare molecular subtypes.

oncology
A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib

Keisuke Kidoguch,Motoharu Shibusawa,Tetsuya Tanimoto

DOI: https://doi.org/10.1007/s10637-021-01151-0

2021-07-15

Investigational New Drugs

Abstract:In the last two decades, simultaneous global development of novel drugs become more common by conducting multiregional clinical trials. However, regulatory authorities of different regions often make different decisions on the approvals of the same new drugs. We would like to discuss the appropriateness of Japanese regulatory approach through a case study of quizartinib, a novel anti-leukemia drug developed in Japan. The pivotal clinical trial "QuANTUM-R" conducted in 19 countries showed a modest increase in median overall survival with quizartinib than the conventional chemotherapy. However, because several critical defects in this trial were pointed out by the United States Food and Drug Administration (US FDA) and the European Medicines Agency (EMA), quizartinib has not been approved in the US and Europe to date. On the contrary, the regulatory authority of Japan gave a notice of approval to quizartinib as a "standard of care", and the country becomes the sole country that granted market authorization. In our paper, we provide more detailed discussion about the methodology for scientific evaluation of the new drug.

oncology,pharmacology & pharmacy
The necessary conduct: Exploratory multiregional clinical trials in East Asia

Inseung Jeon,Yu Kyong Kim,Ildae Song,Deok Yong Yoon,Ki Young Huh,Xuanyou Jin,Kyung‐Sang Yu,SeungHwan Lee,Yuji Kumagai,In‐Jin Jang

DOI: https://doi.org/10.1111/cts.13106

2021-08-16

Clinical and Translational Science

Abstract:Various studies have highlighted the importance of ethnic differences. The consideration of ethnic differences in the field of individualized pharmacotherapy is imperative. Therefore, various organizations and networks across countries should aim to conduct multicountry and multiregional clinical trials (MRCTs). If there is solid evidence available to evaluate the existence of ethnic differences between the same regional areas, it will lead to an increase in the efficiency of drug development. The purpose of this paper was to compare the approval dosing regimen among four Asian countries (Korea, Japan, China, and Taiwan) and elucidate the readiness and current status of the implementation of the International Conference on Harmonization (ICH) E17 guidelines on MRCTs. Reducing unnecessary clinical trials via multinational clinical trials in East Asian countries is also suggested. The approved dosing regimens for some drugs in the four Asian countries were similar; however, some differences might be caused by differences in legislation, even though there were no ethnic differences. This indicates that there are several roles to be expected of the Asia Clinical Pharmacology study network for exploratory MRCTs, which would lead to the accumulation of evidence for MRCTs, ultimately accelerating the efficiency of drug development in East Asian countries. The exposure of the new treatment to the necessary patients through collaborative research coordination and simultaneous multinational subject recruitment would serve its role in providing East Asia with specific personalized medicine with a high treatment success rate.

medicine, research & experimental
Overall safety profile and effectiveness of tramadol hydrochloride/acetaminophen in patients with chronic noncancer pain in Japanese real-world practice

K. Yoshizawa,K. Kawai,M. Fujie,J. Suzuki,Y. Ogawa,T. Yajima,J. Yokomori

DOI: https://doi.org/10.1185/03007995.2015.1091975

2015-09-28

Current Medical Research and Opinion

Abstract:OBJECTIVE: To evaluate the overall safety profile and clinical effectiveness of tramadol hydrochloride/acetaminophen (TA) combination tablets in Japanese patients with chronic noncancer pain unrelieved by non-opioid drugs for up to 12 weeks in real-world practice.RESEARCH DESIGN AND METHODS: This survey was a multicenter, prospective, longitudinal registry on the use of TA as a newly initiated pain treatment for chronic noncancer pain incurable by non-opioid analgesics that was conducted under the Good Post Marketing Study Practice regulation controlled by the Japan Ministry of Health, Labor and Welfare. Collected data included socio-demographics, treatment information, incidence of adverse drug reactions (ADRs), numerical rating scale for intensity of pain, EuroQol-5D (EQ-5D) scale, and physician's global impression (PGI) during the 12 week observation period.RESULTS: A total of 1316 patients were registered. ADRs were reported in 259 patients (20.5%); most events were nonserious (99.4%), including nausea (n = 87 [6.9%]), constipation (n = 63 [5.0%]), dizziness and somnolence (n = 29 [2.3%] each), and vomiting (n = 21 [1.7%]). No event related to drug dependence or respiratory depression was reported. In addition, 82.8% of patients showed acceptable effectiveness based on PGI at Week 4. Numerical rating scale for intensity of pain and EQ-5D utility scores were improved by -2.7 (SD 2.3) and 0.16 (SD 0.20) at Week 4, respectively, and the improvement was maintained until Week 12.CONCLUSION: This is a first report to evaluate the risk-benefit profile of TA in Japanese real-world practice using large size registry data. It is suggested that the favorable risk-benefit balance of TA was confirmed for patients with chronic noncancer pain unrelieved by non-opioid drugs in real-world practice. Limitations of this study were those inherent to open-label and non-interventional study designs.TRIAL REGISTRATION: This registry survey is registered at umin.ac.jp (identifier: UMIN000015901).

medicine, general & internal, research & experimental
Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis

Asami Ezaki,Akihiro Hirakawa,Hideki Hanaoka,Yoshiaki Uyama

DOI: https://doi.org/10.1007/s43441-021-00309-5

2021-06-09

Abstract:A risk management plan (RMP) has an important role in assuring the optimal benefit–risk balance of a drug throughout its life cycle. However, no clear standards have been established for differentiating risk classification between "important identified risks" and "important potential risks". This study was a review and descriptive analysis for Japanese RMPs with a focus on antineoplastic agents to identify effective factors to discriminate an important identified risk from an important potential risk. Analysis based on 51 RMPs, reporting 310 important identified risks and 72 important potential risks, revealed significant associations between selection of the risk classification and several factors, including severe cases, actual cases in the Japanese population, availability of confirmatory trial data, and incidence of adverse events. Trend of the association was also found for discontinuation cases and immune-oncology agents [IO (drug type)]. These results suggest that consideration of these factors may be useful for coherent risk classification in creating a RMP.

pharmacology & pharmacy,medical informatics
Effect of concomitant use of yokukansan on steady-state blood concentrations of donepezil and risperidone in real-world clinical practice

Junji Saruwatari,Tetsuya Kaneko,Tsukasa Murata,Haruka Narise,Sawa Kugimoto,Eri Nishimura,Natsuki Tetsuka,Misaki Ando,Momo Oi,Masako Ota,Nayumi Hamada,Keiichiro Kaneda,Shiro Furusho,Masakatsu Sakamoto,Ayami Kajiwara-Morita,Kazutaka Oda,Kentaro Oniki,Keishi Ueda,Hirofumi Jono,Norio Yasui-Furukori

DOI: https://doi.org/10.1002/npr2.12459

2024-07-08

Abstract:Aim: Yokukansan is one of the most frequently used herbal medicines that can improve the behavioral and psychological symptoms of dementia. In this exploratory study, we investigated whether yokukansan affects the steady-state blood concentrations of donepezil, risperidone, and the major metabolites of both drugs in a real-world clinical setting. Methods: A non-randomized, open-label, single-arm study examining drug-drug interactions was conducted. Fifteen dementia patients taking donepezil for at least 4 weeks and eight schizophrenia patients taking risperidone for at least 2 weeks were orally administered 2.5 g of yokukansan three times a day before or between meals, and blood samples were collected before and 8 weeks after starting co-treatment with yokukansan. Plasma concentrations of donepezil, risperidone, and each metabolite were measured using high-performance liquid chromatography-tandem mass spectrometry and compared before and after the 8-week administration of yokukansan. Results: The plasma concentrations of donepezil and its metabolites (6-O-desmethyl-donepezil, 5-O-desmethyl-donepezil, and donepezil-N-oxide), risperidone, and its metabolite paliperidone did not differ before and after the 8-week treatment with yokukansan. Conclusions: The findings of this study show that the concomitant use of yokukansan may have little clinical impact on the steady-state blood levels of donepezil and risperidone in patients with dementia or schizophrenia.
Cell and gene therapy approvals in Japan and the need for international harmonization

Teruyo Arato,Kaori Nomura

DOI: https://doi.org/10.1038/s41587-023-02053-7

IF: 46.9

2024-01-09

Nature Biotechnology

Abstract:The positions of regulatory agencies on new classes of biomedical products such as cell and gene therapies 1,2,3 have a strong influence on product development but have not been clearly defined. We examined all 17 cell and gene therapies approved as of December 2022 in Japan 4 and compared them to the fates of similar candidate therapies in other countries. This analysis identified notable differences with respect to the use of randomized clinical trials (RCTs), the numbers of participants enrolled, and approaches for evaluating trial results. These differences can be influenced by the use of various accelerated-approval pathways, such as Conditional Early Approval in Japan, the Regenerative Medicine Advance Therapy Designation in the United States, and Priority Medicines in the European Union 5,6 . We conclude that the nascent field of cell and gene therapies would benefit from a concerted effort toward international harmonization with respect to clinical study designs and product approval criteria.

biotechnology & applied microbiology
[Challenges to International Collaborative Clinical Research and Approval Disparities]

Yukinori Ozaki,Toshimi Takano

Abstract:The standard treatment and prognosis of breast cancer are improving as because of international collaborative clinical research. Generally, the standard treatment for breast cancer in Japan is not different from that in the US, Europe or other Asian countries, however, some novel agents have not been developed or have been delayed. For example, no institution in Japan has participated in the clinical trials of sacituzumab-govitecan. Institutions in Japan participated in the clinical trial of alpelisib and neratinib, however, the development of these drugs was delayed due to the racial difference and lack of a company in charge. On the other hand, there are international collaborative trials that Japan has participated in or has taken the lead, such as POSITIVE trial, CREATE-X trial, and PATHWAY trial. There are many challenges for Japan to participate in or lead international collaborative trials with Europe, US, or Asia. It is necessary to build a network and infrastructure for international collaborative trials based on the cooperation between the institutions and clinical trial groups in the world.
Misleading presentations in functional food trials led by contract research organizations were frequently observed in Japan : meta-epidemiological study

Hidehiro Someko,Norio Yamamoto,Tatsuya Ito,Tomoharu Suzuki,Takahiro Tsuge,Hajime Yabuzaki,Eisuke Dohi,Yuki Kataoka

DOI: https://doi.org/10.1016/j.jclinepi.2024.111302

IF: 7.407

2024-02-01

Journal of Clinical Epidemiology

Abstract:OBJECTIVES: The functional food market has experienced significant growth, leading to an uptick in clinical trials conducted by contract research organizations (CROs). Research focusing on CRO-managed trials and the communication of trial outcomes to the consumer market remains underexplored. This metaepidemiological study aims to evaluate the quality of randomized controlled trials (RCTs) facilitated by prominent CROs in Japan and to examine the quality of the representations used to convey their results to consumers.STUDY DESIGN AND SETTING: This study focused on the food trials that were registered in the University Hospital Medical Information Network Clinical Trial Registry or the International Clinical Trials Registry Platform by the top 5 CROs. Press releases of study results or advertisements of food products based on the study results were identified by conducting a Google search. The risk of bias in the RCT publications was independently assessed by 2 reviewers, who also evaluated the presence of "spin" in the abstracts and full texts. An assessment of "spin" in press releases/advertisements was undertaken.RESULTS: A total of 76 RCT registrations, 32 RCT publications, and 11 press releases/advertisements were included. Approximately 72% of the RCT publications exhibited a high risk of bias due to selective outcome reporting. "Spin" was present in the results of the abstract (72%), abstract conclusion (81%), full-text results (44%), and full-text conclusion (84%). "Spin" appeared in 73% of press releases/advertisements due to the selective outcome reporting.CONCLUSION: Functional food presentations in Japan frequently contained "spin." The Japanese government should more rigorously check whether food manufacturers report outcomes selectively.

public, environmental & occupational health,health care sciences & services

Clinical trials: Japan’s opt-out policy raises risks of adverse drug responses

High rate of awarding compensation for claims of injuries related to clinical trials by pharmaceutical companies in Japan: a questionnaire survey

Safety Evaluation and Information Provision for Appropriate Drug Usage in Elderly Patients in Japan

Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan

Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study

Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States: A comparative study of accelerated approvals

Exacerbation rates in Japanese patients with obstructive lung disease: A subanalysis of the prospective, observational NOVELTY study

Assessing Immunogenicity in Drug Reviews and Prescribing Information in Japan

Implementation of Japan's First Clinical Research Regulatory Law: Background, Overview, and Challenges

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan

Guidelines for clinical evaluation of anti‐cancer drugs

Efficacy evaluation of anticancer agents in single-arm clinical trials: analysis of review reports from Pharmaceuticals and Medical Devices Agency

A critical appraisal of Japan's new drug approval process: a case study of FLT3-ITD inhibitor quizartinib

The necessary conduct: Exploratory multiregional clinical trials in East Asia

Overall safety profile and effectiveness of tramadol hydrochloride/acetaminophen in patients with chronic noncancer pain in Japanese real-world practice

Factors Influencing Classifications of Safety Specifications in a Risk Management Plan for Antineoplastic Agents Approved in Japan: A Review and Descriptive Analysis

Effect of concomitant use of yokukansan on steady-state blood concentrations of donepezil and risperidone in real-world clinical practice

Cell and gene therapy approvals in Japan and the need for international harmonization

[Challenges to International Collaborative Clinical Research and Approval Disparities]

Misleading presentations in functional food trials led by contract research organizations were frequently observed in Japan : meta-epidemiological study